مباشر
Endpoints NewsModerna in talks with FDA over Phase 4 Covid vaccine dataEndpoints NewsFDA approves Pfizer and Arvinas' breast cancer drug despite underwhelming dataEndpoints NewsAmgen launches late-stage obesity trial in patients who switch from rival drugsFierceBiotech‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPOBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-April 30, 2026Endpoints NewsQ&A: Seaport CEO and CSO on learning from Karuna and the future of CNS researchBioPharma DiveSummit’s ‘self-inflicted’ stumble; Esperion’s take-private dealBioPharma DiveModerna sees revenue bump from international COVID vaccine salesEndpoints NewsSamsung Biologics workers begin five-day strike over wage disputesFierceBiotechSummit's PD-1xVEGF interim trial miss surprises analysts, shares tumbleEndpoints NewsAcelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China
Malvern Panalytical ٢٠ سبتمبر ٢٠٢٠

Advance with confidence: Malvern Panalytical’s new Zetasizer Pro and Zetasizer Ultra - SelectScience

Advance with confidence: Malvern Panalytical’s new Zetasizer Pro and Zetasizer Ultra - SelectScience

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.